<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The balance between actions of procoagulant and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> factors protects organisms from <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> increases the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp>, and complete quantitative deficiency results in intrauterine <z:mp ids='MP_0010769'>lethality</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>However, patients homozygous for L99F or R47C antithrombin mutations are viable </plain></SENT>
<SENT sid="3" pm="."><plain>These mutations do not modify the folding or secretion of the protein, but abolish the <z:chebi fb="0" ids="18085">glycosaminoglycan</z:chebi>-induced activation of antithrombin by affecting the <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding domain </plain></SENT>
<SENT sid="4" pm="."><plain>We speculated that the natural β-glycoform of antithrombin might compensate for the effect of <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding mutations </plain></SENT>
<SENT sid="5" pm="."><plain>We purified α- and β-antithrombin glycoforms from plasma of 2 homozygous L99F patients </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> affinity chromatography and intrinsic fluorescence kinetic analyses demonstrated that the reduced <z:chebi fb="5" ids="28304">heparin</z:chebi> affinity of the α-L99F glycoform (K(D), 107.9 ± 3nM) was restored in the β-L99F glycoform (K(D), 53.9 ± 5nM) to values close to the activity of α-<z:mp ids='MP_0002169'>wild type</z:mp> (K(D), 43.9 ± 0.4nM) </plain></SENT>
<SENT sid="7" pm="."><plain>Accordingly, the β-L99F glycoform was fully activated by <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Similar results were observed for recombinant R47C and P41L, other <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding antithrombin mutants </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, we identified a new type of mosaicism associated with mutations causing <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding defects in antithrombin </plain></SENT>
<SENT sid="10" pm="."><plain>The presence of a fully functional β-glycoform together with the activity retained by these variants helps to explain the viability of homozygous and the milder thrombotic risk of heterozygous patients with these specific antithrombin mutations </plain></SENT>
</text></document>